Navigation Links
ADVENTRX Completes Acquisition of SynthRx
Date:4/11/2011

SAN DIEGO, April 11, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has completed its acquisition of SynthRx, Inc., now a wholly owned subsidiary of ADVENTRX.  SynthRx's lead product candidate is a novel, proprietary, rheologic and antithrombotic compound, poloxamer 188, that ADVENTRX will develop as ANX-188.

"With ANX-188, we add to our pipeline another late-stage asset with multiple exciting development opportunities.  We plan to meet with FDA this year to reach agreement on a protocol for a pivotal phase 3 study for treatment of sickle cell crisis in a pediatric population, an orphan indication," said Brian M. Culley, Chief Executive Officer of ADVENTRX.  "Because sickle cell crisis is a severe and painful condition often with life-threatening complications and for which existing drugs provide only limited symptomatic relief, there is a significant need to improve treatment options.  Beyond sickle cell, ANX-188 may have clinical utility in other acute events related to microvascular-flow abnormalities, such as heart attack, stroke and hemorrhagic shock."

As previously announced, ADVENTRX and SynthRx entered into a definitive merger agreement in February 2011, which was completed on April 8, 2011.  In connection with the closing, ADVENTRX issued approximately 2.8 million shares of its common stock, of which 862,078 shares (or an approximately 3.3% ownership stake) are vested and approximately 1.9 million are unvested.  The unvested shares will vest upon dosing of the first patient in a phase 3 clinical study meeting certain criteria, subject to reductions based on the timing of dosing of the first patient and the anticipated size of the study. SynthRx stockholders also are entitled to receive additional shares of common stock upon successful achievement of development milestones consisting o
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... According to a new ... Management Market ECG, Implantable Loop Recorder, Manual Event ... Dual Chamber Pacemaker, CRT-D, CRT-P - Global Forecast ... Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices ... 2020 from $21,137.7 Million in 2015, at a ...
(Date:7/3/2015)... , July 3, 2015 ... bekannt, vorbehaltlich bestimmter Abschlussbedingungen eine 100-prozentige Beteiligung ... zu haben. Mit dieser Übernahme dringt Lupin ... einem Umsatz von 765 Mrd. RUB im ... der Welt gehörte (IMS Health). Seit über ...
(Date:7/2/2015)... 2015 Pharma Major Lupin ... participación en ZAO "Biocom" en Rusia bajo ciertas ... de Lupin en el mercado farmacéutico de Rusia ... colocándolo como uno de los 10 principales mercados ... más de una década, el mercado farmacéutico ruso ...
Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3
... 2, 2011 Cynosure, Inc. (NASDAQ: CYNO ), ... and non-invasive aesthetic applications, today announced that it will present ... (ET) on Thursday, June 9 in New York City. ... Davin and Executive Vice President, Treasurer and CFO Timothy Baker ...
... (NASDAQ: BNVI ), a pharmaceutical company focused on ... women,s health and cancer, today announced it will be presenting ... drug candidate for postmenopausal symptoms, Menerba ™ (also known ... World Congress on Menopause in Rome, Italy on June 11, ...
Cached Medicine Technology:Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause 2Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause 3Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause 4
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, ... of technical sales expertise from the North American Board of Certified Energy Practitioners ... the most highly respected and well established national certification organization for renewable energy ...
(Date:7/3/2015)... , ... July 03, 2015 ... ... the sessions and speaker lineup for its 2015 Annual Conference , ... August 6-8, 2015 at the Renaissance Orlando at SeaWorld in Orlando, Florida. ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national chief nursing officer recruitment for ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
(Date:7/3/2015)... ... July 03, 2015 , ... Jennifer Renee Hanes, DO is ... Room , the largest network of independent freestanding emergency rooms in the United States. ... of our Sienna Plantation facility,” said Executive Medical Director of First Choice Emergency Room, ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Every year, ... 24-Hour Train-a-Thon where they provide members of the Red Deer community with free fitness ... day of fitness training, games, food, events and entertainment raised thousands of charity dollars ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3
... may extend or shorten life, study finds , THURSDAY, ... to longer survival for ovarian cancer patients, U.S. researchers ... incident epithelial ovarian cancer, the researchers found that higher ... and healthy grain consumption were associated with longer survival. ...
... ... ... ... ...
... Boston, MA Researchers from the Harvard School of Public ... of collaborators have observed for the first time that the ... infection with the Epstein-Barr virus (EBV). This finding implicates EBV ... in an advance online edition of the journal Annals of ...
... ... ... ... ...
... ... ... , ... , , , , ...
... EEG study conducted on college students at American ... mode network, a suggested natural "ground state" of the ... This three-month randomized control study is published in a ... dedicated to the Neuroscience of Meditation and Consciousness, Volume ...
Cached Medicine News:Health News:Pre-Diagnosis Diet Linked to Ovarian Cancer Survival 2Health News:Anthera Pharmaceuticals Completes Initial Public Offering 2Health News:Anthera Pharmaceuticals Completes Initial Public Offering 3Health News:Anthera Pharmaceuticals Completes Initial Public Offering 4Health News:Anthera Pharmaceuticals Completes Initial Public Offering 5Health News:Anthera Pharmaceuticals Completes Initial Public Offering 6Health News:Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis 2Health News:Psoriasis is More Than Skin Deep 2Health News:Psoriasis is More Than Skin Deep 3Health News:Psoriasis is More Than Skin Deep 4Health News:Psoriasis is More Than Skin Deep 5Health News:Psoriasis is More Than Skin Deep 6Health News:Psoriasis is More Than Skin Deep 7Health News:Psoriasis is More Than Skin Deep 8Health News:Founder and President of BOMF, Anne Mahlum, Speaks on How Running Helps to Tackle Homelessness, at National Press Club 2Health News:Transcendental Meditation activates default mode network, the brain's natural ground state 2
Anti-RSV IgA Assay (ELISA)....
... SAS RSV antigen test is ... for the presumptive qualitative detection ... from nasopharyngeal specimens in neonatal ... 15 minute test has a ...
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Medicine Products: